Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 3/20 | 0.67 |
| ▸ | CES1 | P23141 | 3/20 | 0.67 |
| ▸ | KCNQ3 | O43525 | 4/20 | 0.47 |
| ▸ | KCNQ2 | O43526 | 4/20 | 0.47 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.47 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.47 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.44 |
| ▸ | CHRNG | P07510 | 1/20 | 0.44 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.44 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.44 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | CHRND | Q07001 | 1/20 | 0.44 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29470947 | 1.00 | CES2 (0.67) | CES2CES1KCNQ3KCNQ2KCNE1 | |
| SCHEMBL4957103 | 0.82 | ALDH1A1 (0.54) | CES2CES1KCNQ3KCNQ2KCNE1 | |
| SCHEMBL3026551 | 0.82 | KCNQ3 (0.51) | CES2CES1KCNQ3KCNQ2KCNE1 | |
| SCHEMBL193605 | 0.82 | KCNQ3 (0.51) | CES2CES1KCNQ3KCNQ2KCNE1 | |
| SCHEMBL11669995 | 0.82 | ALDH1A1 (0.54) | CES2CES1KCNQ3KCNQ2KCNE1 | |
| SCHEMBL18707178 | 0.82 | KDM4E (0.53) | CES2CES1POLB | |
| SCHEMBL13012035 | 0.80 | CES2 (0.43) | CES2CES1MEN1KMT2AALDH1A1 | |
| SCHEMBL789006 | 0.80 | CES2 (0.43) | CES2CES1KCNQ3KCNQ2KCNE1 | |
| SCHEMBL925050 | 0.80 | HDAC1 (0.61) | CES2CES1KCNQ3KCNQ2KCNE1 | |
| SCHEMBL146573 | 0.80 | NPC1 (0.46) | CES2CES1RAB9AALDH1A1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1098 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117624140-A | CXCR4 antagonists, methods of making and uses thereof | 杭州师范大学 | 2024-03-01 | — | — | CN | claimed |
| CN-113307768-B | Quinolone derivative and preparation method and application thereof | 中国农业科学院兰州畜牧与兽药研究所 | 2023-12-12 | — | — | CN | claimed |
| CN-113773264-A | Pyrimidine amide compound applied to herbicide and preparation method thereof | 池州飞昊达化工有限公司 | 2021-12-10 | — | — | CN | claimed |
| CN-110143941-B | Synthesis method of intermediate of balusavir mefene | 北京四环制药有限公司 | 2021-05-25 | — | — | CN | claimed |
| CN-111542319-A | Fused bicyclic compounds | 阿卡纳治疗学有限公司 | 2020-08-14 | — | — | CN | claimed |
| EP-3630100-A1 | FUSED BICYCLIC COMPOUNDS | Akarna Therapeutics, Ltd. (GB) | 2020-04-08 | — | — | EP | claimed |
| CN-110143941-A | A kind of synthetic method of Barrow Sa Weimabo ester intermediate | 北京四环制药有限公司 | 2019-08-20 | — | — | CN | claimed |
| WO-2018222876-A1 | FUSED BICYCLIC COMPOUNDS | AKARNA THERAPEUTICS, LTD. (GB) | 2018-12-06 | — | — | WO | claimed |
| CN-106831814-B | A kind of thieno [3,2-d] miazines HIV-1 reverse transcriptase inhibitor and its preparation method and application | 山东大学 | 2018-11-23 | — | — | CN | claimed |
| CN-106831814-A | A kind of thieno [3,2 d] RTIs of miazines HIV 1 and its preparation method and application | 山东大学 | 2017-06-13 | — | — | CN | claimed |
| CN-1785993-B | Preparation and use of non-natural isocoumarin derivatives | UNIV NANKAI | 2012-03-14 | — | — | CN | claimed |
| US-6384031-B1 | — | — | None | — | — | US | disclosed |
| EP-4713018-A1 | TRANSFECTION COMPOSITIONS SUITABLE FOR PRODUCING A BIOLOGICAL PRODUCT | PolyPlus Transfection (FR) | 2026-03-25 | — | — | EP | disclosed |
| US-20250353850-A1 | CYCLIC AMIDE-CONTAINING PYRIDYL XANTHINES AS A2B ANTAGONISTS | ADOVATE LLC (US) | 2025-11-20 | — | — | US | disclosed |
| EP-3699174-B1 | COMPOSITION FOR PREVENTING OR TREATING TNF-RELATED DISEASES, CONTAINING DERIVATIVE AS ACTIVE INGREDIENT, AND METHOD FOR INHIBITING TNF ACTIVITY BY USING SAME | ILAB (KR) | 2025-11-12 | — | — | EP | disclosed |
| US-4179501-A | Analgesic N-(2-aminocycloaliphatic)azidobenzamides | THE UPJOHN COMPANY (US) | 1979-12-18 | — | — | US | disclosed |
| US-4153717-A | 260/332.2 R | THE UPJOHN COMPANY (US) | 1979-05-08 | — | — | US | disclosed |
| US-4152459-A | Analgesic N-2-(aminocycloaliphatic)-hydroxy, alkoxy and (allylic)alkenyloxy-benzamides | THE UPJOHN COMPANY (US) | 1979-05-01 | — | — | US | disclosed |
| US-4148914-A | Analgesic N-(2-aminocyclo aliphatic)cyanobenzamides | THE UPJOHN COMPANY (US) | 1979-04-10 | — | — | US | disclosed |
| US-4098904-A | ANALGESIC N-(2-AMINOCYCLOALIPHATIC)BENZAMIDES | THE UPJOHN COMPANY (US) | 1978-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250353850-A1 | CYCLIC AMIDE-CONTAINING PYRIDYL XANTHINES AS A2B ANTAGONISTS | ADORA2B, ADORA2A, ADORA1 | CES2 1622/4885CES1 1055/4885KCNQ3 2806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.